ALK1 antagonists and their uses in treating renal cell carcinoma
摘要
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit tumor growth of renal cell carcinoma (RCC) in vivo. In additional aspects the disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of ALK1 dramatically increases the ability of a standard of care receptor tyrosine kinase inhibitor to inhibit RCC tumor growth in vivo.
申请公布号
AU2013214779(A1)
申请公布日期
2014.09.04
申请号
AU20130214779
申请日期
2013.02.01
申请人
BETH ISRAEL DEACONESS MEDICAL CENTER;ACCELERON PHARMA INC.
发明人
BHATT, RUPAL S.;KUMAR, RAVINDRA;MIER, JAMES W.;PEARSALL, ROBERT;SHERMAN, MATTHEW;SOLBAN, NICOLAS